NCT05188781View on ClinicalTrials.gov

Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

CompletedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

August 23, 2021

Study Completion Date

August 23, 2021

Conditions
High-Grade Serous Ovarian Cancer
Interventions
DRUG

Pembrolizumab combined Anlotinib

Pembrolizumab 200 mg every 3 weeks, Anlotinib 12 mg/day, orally;2weeks treatment followed by 1week off

Trial Locations (1)

266003

Xiaochun Zhang, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER

NCT05188781 - Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer | Biotech Hunter | Biotech Hunter